Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia
Launched by NOVO NORDISK A/S · Nov 30, 2022
Trial Information
Current as of January 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Signed consent obtained before any study related activities (study related activities are any procedure-related to recording of data according to the protocol).
- • 2. Diagnosed with obesity (BMI higher than or equal to 30 for all ethnic groups except Asian; BMI higher than or equal to 27.5 for patients of Asian ethnicity).
- • 3. Diagnosed with T2D for patients in Cohort 2.
- • 4. Male or female, aged between 18 and 75 years at the time of signing informed consent
- Exclusion Criteria:
- • 1. Participation in an interventional clinical trial during the study period.
- • 2. Diagnosed with T2D for patients in Cohort 1.
- • 3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Trial Officials
Clinical Transparency (dept. 2834)
Study Director
Novo Nordisk A/S
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Riyadh, , Saudi Arabia
Al Ahsa, , Saudi Arabia
Dammam, , Saudi Arabia
Ihsaa, , Saudi Arabia
Jeddah, , Saudi Arabia
Jeddah, , Saudi Arabia
Riyadh, , Saudi Arabia
Al Ahsa, , Saudi Arabia
Riyadh, , Saudi Arabia
Jeddah, , Saudi Arabia
Dammam, , Saudi Arabia
Jeddah, , Saudi Arabia
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials